Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316464102> ?p ?o ?g. }
- W4316464102 endingPage "294" @default.
- W4316464102 startingPage "294" @default.
- W4316464102 abstract "Liposome-based drug delivery systems are nanosized spherical lipid bilayer carriers that can encapsulate a broad range of small drug molecules (hydrophilic and hydrophobic drugs) and large drug molecules (peptides, proteins, and nucleic acids). They have unique characteristics, such as a self-assembling bilayer vesicular structure. There are several FDA-approved liposomal-based medicines for treatment of cancer, bacterial, and viral infections. Most of the FDA-approved liposomal-based therapies are in the form of conventional symmetric liposomes and they are administered mainly by injection. Arikace® is the first and only FDA-approved liposomal-based inhalable therapy (amikacin liposome inhalation suspension) to treat only adults with difficult-to-treat Mycobacterium avium complex (MAC) lung disease as a combinational antibacterial treatment. To date, no asymmetric liposomes are yet to be approved, although asymmetric liposomes have many advantages due to the asymmetric distribution of lipids through the liposome's membrane (which is similar to the biological membranes). There are many challenges for the formulation and stability of asymmetric liposomes. This review will focus on asymmetric liposomes in contrast to conventional liposomes as a potential clinical intervention drug delivery system as well as the formulation techniques available for symmetric and asymmetric liposomes. The review aims to renew the research in liposomal nanovesicle delivery systems with particular emphasis on asymmetric liposomes as future potential carriers for enhancing drug delivery including pulmonary nanotherapeutics." @default.
- W4316464102 created "2023-01-16" @default.
- W4316464102 creator A5018926186 @default.
- W4316464102 creator A5029065268 @default.
- W4316464102 creator A5056884838 @default.
- W4316464102 date "2023-01-15" @default.
- W4316464102 modified "2023-10-16" @default.
- W4316464102 title "Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics" @default.
- W4316464102 cites W137910282 @default.
- W4316464102 cites W1544573343 @default.
- W4316464102 cites W1585705786 @default.
- W4316464102 cites W1702860740 @default.
- W4316464102 cites W1762620449 @default.
- W4316464102 cites W1849224908 @default.
- W4316464102 cites W1973285493 @default.
- W4316464102 cites W1977884403 @default.
- W4316464102 cites W1977986845 @default.
- W4316464102 cites W1978591779 @default.
- W4316464102 cites W1979094684 @default.
- W4316464102 cites W1984485776 @default.
- W4316464102 cites W1990356838 @default.
- W4316464102 cites W1990973079 @default.
- W4316464102 cites W2006831581 @default.
- W4316464102 cites W2007293468 @default.
- W4316464102 cites W2016689892 @default.
- W4316464102 cites W2021882008 @default.
- W4316464102 cites W2027504135 @default.
- W4316464102 cites W2033712682 @default.
- W4316464102 cites W2034636421 @default.
- W4316464102 cites W2037735248 @default.
- W4316464102 cites W2039786638 @default.
- W4316464102 cites W2042481140 @default.
- W4316464102 cites W2044609602 @default.
- W4316464102 cites W2049778626 @default.
- W4316464102 cites W2050410538 @default.
- W4316464102 cites W2067772112 @default.
- W4316464102 cites W2080720583 @default.
- W4316464102 cites W2085420819 @default.
- W4316464102 cites W2088654227 @default.
- W4316464102 cites W2091185388 @default.
- W4316464102 cites W2091650131 @default.
- W4316464102 cites W2096474273 @default.
- W4316464102 cites W2097603366 @default.
- W4316464102 cites W2098419906 @default.
- W4316464102 cites W2106910882 @default.
- W4316464102 cites W2112679913 @default.
- W4316464102 cites W2121354606 @default.
- W4316464102 cites W2134634622 @default.
- W4316464102 cites W2136319664 @default.
- W4316464102 cites W2136558879 @default.
- W4316464102 cites W2140063223 @default.
- W4316464102 cites W2141367941 @default.
- W4316464102 cites W2165394771 @default.
- W4316464102 cites W2165735762 @default.
- W4316464102 cites W2167334120 @default.
- W4316464102 cites W2170572335 @default.
- W4316464102 cites W2344639713 @default.
- W4316464102 cites W2439033168 @default.
- W4316464102 cites W2442713952 @default.
- W4316464102 cites W2490721346 @default.
- W4316464102 cites W2555973348 @default.
- W4316464102 cites W2559947736 @default.
- W4316464102 cites W2570105991 @default.
- W4316464102 cites W2761074176 @default.
- W4316464102 cites W2766926221 @default.
- W4316464102 cites W2768031183 @default.
- W4316464102 cites W2781647603 @default.
- W4316464102 cites W2793362907 @default.
- W4316464102 cites W2888937628 @default.
- W4316464102 cites W2911432198 @default.
- W4316464102 cites W2923713965 @default.
- W4316464102 cites W2966860964 @default.
- W4316464102 cites W2966939253 @default.
- W4316464102 cites W2969576243 @default.
- W4316464102 cites W2976963608 @default.
- W4316464102 cites W2980281910 @default.
- W4316464102 cites W2991641956 @default.
- W4316464102 cites W3005903109 @default.
- W4316464102 cites W3017884767 @default.
- W4316464102 cites W3040859487 @default.
- W4316464102 cites W3087028313 @default.
- W4316464102 cites W3092236733 @default.
- W4316464102 cites W3093244933 @default.
- W4316464102 cites W3095001350 @default.
- W4316464102 cites W3105191084 @default.
- W4316464102 cites W3125853620 @default.
- W4316464102 cites W3133496565 @default.
- W4316464102 cites W3176970273 @default.
- W4316464102 cites W3187024644 @default.
- W4316464102 cites W3198988076 @default.
- W4316464102 cites W3213725099 @default.
- W4316464102 cites W4210301686 @default.
- W4316464102 cites W4214731444 @default.
- W4316464102 cites W4234894168 @default.
- W4316464102 cites W4286635933 @default.
- W4316464102 cites W63612215 @default.
- W4316464102 doi "https://doi.org/10.3390/pharmaceutics15010294" @default.
- W4316464102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36678922" @default.